In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting, in San Francisco, researchers will present findings that show that the use ...
OBJECTIVES: 17-Hydroxyprogesterone, an intermediary hormone in cortisol synthesis, has been shown to be elevated in premature infants. However, the relationship between levels of ...
February 15, 2007 (San Francisco) — High-dose 17-alpha hydroxyprogesterone in women at risk for preterm labor effectively prevents preterm delivery by inhibiting cervical ripening and by blocking ...
One of the more dramatic studies presented at the 23rd Annual Meeting of the Society for Maternal-Fetal Medicine, held February 3-8, 2003 in San Francisco, California, involved the resurrection of an ...
Please provide your email address to receive an email when new articles are posted on . The FDA initially approved 17-hydroxyprogesterone caproate (17-OHPC), marketed under the brand name Delalutin ...
Please provide your email address to receive an email when new articles are posted on . Hydroxyprogesterone caproate is not recommended to prevent recurrent preterm birth. Vaginal progesterone may be ...
The use of the hormone 17-Hydroxyprogesterone does not reduce the rate of preterm delivery or neonatal complications in twins, study suggests. In a study to be presented February 10 at the Society for ...
SAN FRANCISCO (February 10, 2011) — In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting ™, in San Francisco, researchers will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback